Also found in: Dictionary, Wikipedia.


Ebixa (CA) (UK), Namenda

Pharmacologic class: N-methyl-D-aspartate receptor antagonist (NMDA)

Therapeutic class: Anti-Alzheimer's agent

Pregnancy risk category B


Unclear. Thought to act as a low- to moderate-affinity NMDA receptor antagonist, binding to NMDA receptor-operated channels. (Activation of these channels is thought to contribute to Alzheimer's symptoms.)


Oral solution: 2 mg/ml

Tablets: 5 mg, 10 mg

Tablets (titration pack): 28 tablets of 5 mg and 21 tablets of 10 mg

Indications and dosages

Moderate to severe Alzheimer's-type dementia

Adults: Initially, 5 mg P.O. daily. Then titrate at intervals of at least 1 week in 5-mg increments, to a maximum of 10 mg P.O. b.i.d.

Dosage adjustment

• Moderate renal impairment


• Hypersensitivity to drug or its components


Use cautiously in:
• neurologic conditions, moderate to severe renal impairment, genitourinary conditions that increase pH
• pregnant or breastfeeding patients.


• Give with or without food.

Adverse reactions

CNS: dizziness, headache, syncope, aggressive reaction, confusion, somnolence, hallucinations, agitation, insomnia, vertigo, ataxia, abnormal gait, hypokinesia, anxiety, transient ischemic attack, cerebrovascular accident (CVA)

CV: hypertension, cardiac failure

EENT: cataract, conjunctivitis

GI: nausea, vomiting, diarrhea, constipation, anorexia

GU: frequent voiding, urinary incontinence, urinary tract infection

Hematologic: anemia

Musculoskeletal: back pain, arthralgia

Respiratory: cough, dyspnea, bronchitis, pneumonia

Skin: rash

Other: weight loss, fatigue, pain, falls, flulike symptoms, peripheral edema


Drug-drug.Cimetidine, hydrochlorothiazide, nicotine, quinidine, ranitidine, triamterene: altered blood levels of both drugs

Urine-alkalizing drugs (carbonic anhydrase inhibitors, sodium bicarbonate): decreased memantine elimination

Drug-diagnostic tests.Alkaline phosphatase: increased level

Patient monitoring

Check for heart failure and signs and symptoms of CVA.
• Monitor kidney function tests.

Patient teaching

• Tell patient to take with or without food.
• Instruct patient or caregiver not to mix solution with other liquids and to take or give oral solution only with included dosing device.
• Make sure patient or caregiver understands dose escalation.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


A drug, C20H24N5O4, used in its hydrochloride form to treat symptoms of Alzheimer's disease by inhibiting NMDA receptors.


an anti-Alzheimer agent.
indications This drug is used to treat moderate to severe dementia in Alzheimer's disease.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Adverse effects of this drug include somnolence, headache, hallucinations, hypertension, vomiting, constipation, rash, coughing, dyspnea, back pain, fatigue, and pain. Common side effects include dizziness and confusion.


An NMDA (N-methyl D-aspartate) receptor antagonist that counters the toxic effects of glutamate excess to manage the symptoms of moderate to severe Alzheimer’s disease.

Adverse effects
Hallucinations, confusion, dizziness, headache, hypertonia, nausea, vomiting, constipation, hypertonia, cystitis, increased libido.
Proposed mechanism
Interferes with homocysteine binding at the NMDA receptor; homocysteine also mediates excitotoxicity, and disturbs glutamatergic neurotransmission.


An inhibitor of glutamate NMDA RECEPTORS used with the expectation of delaying the progress of ALZHEIMER'S DISEASE and other forms of dementia. It has been shown to have some value even in the later stages of dementia. A brand name is Ebixa.
References in periodicals archive ?
Nice chief executive, Sir Andrew Dillon said: "Since 2007 clinical trials have continued to show the positive effects of these drugs and, in the case of memantine, have reduced the uncertainty about its clinical effectiveness.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal 111) provides the following guidance for the National Health Service in England and Wales for Ebixa(R) (memantine)1:
Therefore, she was prescribed a memantine titration pack, 5 mg daily and increased over a month to 10 mg twice daily.
The National Institute for Clinical Excellence (NICE) confirmed Memantine will soon no longer be recommended as a treatment for people with severe Alzheimer's.
Researchers report in the January Archives of Neurology that 66 people taking memantine for Alzheimer's disease continued to benefit for a year, the longest test of the drug to date, says coauthor Barry Reisberg, a geriatric psychiatrist at New York University School of Medicine.
In this study, 63 patients with fibromyalgia were randomized to 20 mg/day of memantine or matching placebo for a total of 6 months, including an initial 1-month up-titration period.
The year ended June 2015 entire sales of Memantine Hydrochloride Oral Solution 2 mg/mL at Average Wholesale Price (AWP) were around $12 million, said IMS.
The first randomized patients to 10 mg memantine or placebo plus donepezil.
That is where the Alzheimer's drug memantine comes in.
Memantine slows down dementia by reducing the amount of a brain chemical called glutamate.
While vitamin E and memantine have known benefits for those with moderately severe Alzheimer's disease (AD), the effects on mild to moderate AD have been limited.